Core Insights - The company, Weigao Blood Purification, closed at 36.39 yuan on June 24, with a 1.45% increase, resulting in a rolling PE ratio of 32.72 times and a total market capitalization of 14.971 billion yuan [1][2] - The average PE ratio in the medical device industry is 49.12 times, with a median of 36.07 times, placing Weigao Blood Purification at the 71st position in the industry ranking [1][2] - As of May 19, 2025, the number of shareholders increased to 59,754, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Company Overview - Weigao Blood Purification specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis fluid [1] - The company holds the largest market share in China for blood dialysis devices at 32.5% and blood dialysis tubing at 32.8% as of 2022 [1] - The company also ranks fifth in the domestic market for peritoneal dialysis fluid with a market share of 3.6% for the Weigao Tailmao brand [1] Financial Performance - In the first quarter of 2025, the company reported a revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91% year-on-year [2] - The gross profit margin for the company stands at 40.92% [2]
威高血净收盘上涨1.45%，滚动市盈率32.72倍，总市值149.71亿元